{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:40:22Z","timestamp":1789497622042,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-38707-0","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T02:56:18Z","timestamp":1770778578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of SNVs on adverse reactions and survival in gefitinib-treated lung cancer patients from a preliminary study"],"prefix":"10.1038","volume":"16","author":[{"given":"Mariana Vieira","family":"Morau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cec\u00edlia Souto","family":"Seguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Mauricio Wesley","family":"Perroud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Dagli-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovana Fernanda Santos","family":"Fidelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eder","family":"de Carvalho Pincinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Moriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"38707_CR1","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1056\/NEJMra1703413","volume":"377","author":"M Reck","year":"2017","unstructured":"Reck, M. & Rabe, K. F. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl. J. Med. 377, 849\u2013861 (2017).","journal-title":"N Engl. J. Med."},{"key":"38707_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"38707_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter, A., Veluswamy, R. R. & Wisnivesky, J. P. The global burden of lung cancer: current status and future trends. Nat. Rev. Clin. Oncol. 20, 624\u2013639 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"38707_CR4","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1158\/1078-0432.CCR-15-2266","volume":"22","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian, D. et al. FDA approval of gefitinib for the treatment of patients with metastatic EGFR mutation-positive non-small cell lung cancer. Clin. Cancer Res. 22, 1307\u20131312 (2016).","journal-title":"Clin. Cancer Res."},{"key":"38707_CR5","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","volume":"10","author":"MH Cohen","year":"2004","unstructured":"Cohen, M. H. et al. United States food and drug administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10, 1212\u20131218 (2004).","journal-title":"Clin. Cancer Res."},{"key":"38707_CR6","doi-asserted-by":"publisher","unstructured":"Miller, M. & Hanna, N. Advances in systemic therapy for non-small cell lung cancer. BMJ n2363 https:\/\/doi.org\/10.1136\/bmj.n2363 (2021).","DOI":"10.1136\/bmj.n2363"},{"key":"38707_CR7","doi-asserted-by":"crossref","unstructured":"Costanzo, R. et al. Gefitinib in non small cell lung cancer. Biomed Res. Int. (2011).","DOI":"10.1155\/2011\/815269"},{"key":"38707_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1200\/JCO.2012.43.0652","volume":"31","author":"T Mok","year":"2013","unstructured":"Mok, T., Yang, J. J. & Lam, K. C. Treating patients with EGFR-sensitizing mutations: first line or second line\u2014is there a difference? J. Clin. Oncol. 31, 1081\u20131088 (2013).","journal-title":"J. Clin. Oncol."},{"key":"38707_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3310\/hta14Suppl2-10","volume":"14","author":"T Brown","year":"2010","unstructured":"Brown, T. et al. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol. Assess. (Rockv). 14, 71\u201379 (2010).","journal-title":"Health Technol. Assess. (Rockv)"},{"key":"38707_CR10","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1038\/nrdp.2015.9","volume":"1","author":"C Gridelli","year":"2015","unstructured":"Gridelli, C. et al. Non-small-cell lung cancer. Nat. Rev. Dis. Prim. 1, 15009 (2015).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"38707_CR11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1007\/s11033-024-09865-z","volume":"51","author":"X Kang","year":"2024","unstructured":"Kang, X., Li, R., Li, X. & Xu, X. EGFR mutations and abnormal trafficking in cancers. Mol. Biol. Rep. 51, 924 (2024).","journal-title":"Mol. Biol. Rep."},{"key":"38707_CR12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1517\/14740338.5.3.469","volume":"5","author":"RJ Cersosimo","year":"2006","unstructured":"Cersosimo, R. J. Gefitinib: an adverse effects profile. Expert Opin. Drug Saf. 5, 469\u2013479 (2006).","journal-title":"Expert Opin. Drug Saf."},{"key":"38707_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.toxlet.2021.02.003","volume":"343","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Mechanism of hepatotoxicity of first-line tyrosine kinase inhibitors: gefitinib and afatinib. Toxicol. Lett. 343, 1\u201310 (2021).","journal-title":"Toxicol. Lett."},{"key":"38707_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.critrevonc.2017.03.032","volume":"114","author":"RD Hofheinz","year":"2017","unstructured":"Hofheinz, R. D., Segaert, S., Safont, M. J., Demonty, G. & Prenen, H. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Crit. Rev. Oncol. Hematol. 114, 102\u2013113 (2017).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"38707_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1001\/jamadermatol.2015.4448","volume":"152","author":"KL Chen","year":"2016","unstructured":"Chen, K. L. et al. Comparison of skin toxic effects associated with gefitinib, erlotinib, or afatinib treatment for non-small cell lung cancer. JAMA Dermatol. 152, 340 (2016).","journal-title":"JAMA Dermatol"},{"key":"38707_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.cllc.2013.03.003","volume":"14","author":"T Takimoto","year":"2013","unstructured":"Takimoto, T. et al. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. Clin. Lung Cancer. 14, 502\u2013507 (2013).","journal-title":"Clin. Lung Cancer"},{"key":"38707_CR17","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","volume":"290","author":"MG Kris","year":"2003","unstructured":"Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149\u20132158 (2003).","journal-title":"JAMA"},{"key":"38707_CR18","doi-asserted-by":"crossref","unstructured":"Cacabelos, R., Naidoo, V., Corzo, L., Cacabelos, N. & Carril, J. C. Genophenotypic factors and pharmacogenomics in adverse drug reactions. Int. J. Mol. Sci. 22, 407\u2013442 (2021).","DOI":"10.3390\/ijms222413302"},{"key":"38707_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/anae.14143","volume":"73","author":"K Patton","year":"2018","unstructured":"Patton, K. & Borshoff, D. C. Adverse drug reactions. Anaesthesia 73, 76\u201384 (2018).","journal-title":"Anaesthesia"},{"key":"38707_CR20","doi-asserted-by":"crossref","unstructured":"Micaglio, E. et al. Role of pharmacogenetics in adverse drug reactions: an update towards personalized medicine. Front. Pharmacol. 12, 651720 (2021).","DOI":"10.3389\/fphar.2021.651720"},{"key":"38707_CR21","doi-asserted-by":"publisher","unstructured":"Alfirevic, A. & Pirmohamed, M. Pharmacogenetics and Pharmacogenomics. in Medical and Health Genomics 121\u2013137 (Elsevier, 2016). https:\/\/doi.org\/10.1016\/B978-0-12-420196-5.00010-1","DOI":"10.1016\/B978-0-12-420196-5.00010-1"},{"key":"38707_CR22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/pathogens8040168","volume":"8","author":"A Nogales","year":"2019","unstructured":"Nogales, A. & DeDiego, L. Host single nucleotide polymorphisms modulating influenza A virus disease in humans. Pathogens 8, 168 (2019).","journal-title":"Pathogens"},{"key":"38707_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/00498250400026464","volume":"35","author":"D Mckillop","year":"2005","unstructured":"Mckillop, D. et al. Cytochrome P450-dependent metabolism of gefitinib. Xenobiotica 35, 39\u201350 (2005).","journal-title":"Xenobiotica"},{"key":"38707_CR24","first-page":"1","volume":"13","author":"C Zhao","year":"2017","unstructured":"Zhao, C., Shuyan, H. & Li, P. P. Pharmacokinetics of gefitinb: roles of drug metabolizing enzymes and transporters. Curr. Drug Deliv. 13, 1 (2017).","journal-title":"Curr. Drug Deliv."},{"key":"38707_CR25","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1124\/mol.65.6.1485","volume":"65","author":"C \u00d6zvegy-Laczka","year":"2004","unstructured":"\u00d6zvegy-Laczka, C. et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 65, 1485\u20131495 (2004).","journal-title":"Mol. Pharmacol."},{"key":"38707_CR26","doi-asserted-by":"crossref","unstructured":"Culy, C. R. & Faulds, D. Gefitinib. Drugs 62, 2237\u20132248 (2002).","DOI":"10.2165\/00003495-200262150-00008"},{"key":"38707_CR27","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1038\/s41598-020-63265-4","volume":"10","author":"I Zawadzka","year":"2020","unstructured":"Zawadzka, I. et al. The impact of ABCB1 gene polymorphism and its expression on non-small-cell lung cancer development, progression and therapy-preliminary report. Sci. Rep. 10, 6188 (2020).","journal-title":"Sci. Rep."},{"key":"38707_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/tpj.2016.31","volume":"17","author":"Y Ma","year":"2017","unstructured":"Ma, Y. et al. Determinants of gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. Pharmacogenom. J. 17, 325\u2013330 (2017).","journal-title":"Pharmacogenom. J."},{"key":"38707_CR29","first-page":"133","volume":"74","author":"M Tamura","year":"2012","unstructured":"Tamura, M. et al. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (abcg2, abcb1) and gefitinib toxicity. Nagoya J. Med. Sci. 74, 133\u2013140 (2012).","journal-title":"Nagoya J. Med. Sci."},{"key":"38707_CR30","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2147\/OTT.S154244","volume":"11","author":"L Tang","year":"2018","unstructured":"Tang, L. et al. Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis. Onco Targets Ther. 11, 665\u2013675 (2018).","journal-title":"Onco Targets Ther."},{"key":"38707_CR31","doi-asserted-by":"crossref","unstructured":"Kersey, P. J. et al. Ensembl genomes: scaling up access to genome-wide data. Nucleic Acids Res. 42, D546\u2013D552 (2013).","DOI":"10.1093\/nar\/gkt979"},{"key":"38707_CR32","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/humu.23220","volume":"38","author":"MS Naslavsky","year":"2017","unstructured":"Naslavsky, M. S. et al. Exomic variants of an elderly cohort of Brazilians in the ABraOM database. Hum. Mutat. 38, 751\u2013763 (2017).","journal-title":"Hum. Mutat."},{"key":"38707_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2169\/internalmedicine.51.6285","volume":"51","author":"K Kunimasa","year":"2012","unstructured":"Kunimasa, K. et al. Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity. Intern. Med. 51, 431\u2013434 (2012).","journal-title":"Intern. Med."},{"key":"38707_CR34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.lungcan.2010.08.012","volume":"70","author":"GY Ku","year":"2010","unstructured":"Ku, G. Y., Chopra, A. & de Lopes, G. Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. Lung Cancer. 70, 223\u2013225 (2010).","journal-title":"Lung Cancer"},{"key":"38707_CR35","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","volume":"21","author":"M Fukuoka","year":"2003","unstructured":"Fukuoka, M. et al. Multi-Institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21, 2237\u20132246 (2003).","journal-title":"J. Clin. Oncol."},{"key":"38707_CR36","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/CAD.0000000000000622","volume":"29","author":"YH Park","year":"2018","unstructured":"Park, Y. H. et al. Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity. Anticancer Drugs. 29, 471\u2013476 (2018).","journal-title":"Anticancer Drugs"},{"key":"38707_CR37","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1200\/JCO.2006.05.7109","volume":"24","author":"N Seki","year":"2006","unstructured":"Seki, N., Uematsu, K., Shibakuki, R. & Eguchi, K. Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration. J. Clin. Oncol. 24, 3213\u20133214 (2006).","journal-title":"J. Clin. Oncol."},{"key":"38707_CR38","doi-asserted-by":"publisher","first-page":"e273","DOI":"10.1200\/JCO.2009.26.5496","volume":"28","author":"M Takeda","year":"2010","unstructured":"Takeda, M., Okamoto, I., Fukuoka, M. & Nakagawa, K. Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. J. Clin. Oncol. 28, e273\u2013e274 (2010).","journal-title":"J. Clin. Oncol."},{"key":"38707_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/ncponc1087","volume":"5","author":"Y Loriot","year":"2008","unstructured":"Loriot, Y. et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat. Clin. Pract. Oncol. 5, 268\u2013278 (2008).","journal-title":"Nat. Clin. Pract. Oncol."},{"key":"38707_CR40","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s00204-014-1244-4","volume":"88","author":"S Pastore","year":"2014","unstructured":"Pastore, S., Lulli, D. & Girolomoni, G. Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. Arch. Toxicol. 88, 1189\u20131203 (2014).","journal-title":"Arch. Toxicol."},{"key":"38707_CR41","doi-asserted-by":"crossref","unstructured":"Li, Y. et al. Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies. Front Oncol. 12, 804212 (2022).","DOI":"10.3389\/fonc.2022.804212"},{"key":"38707_CR42","first-page":"301","volume":"11","author":"H Jiang","year":"2019","unstructured":"Jiang, H., Zhu, M., Li, Y. & Li, Q. Association between Egfr exon 19 or exon 21 mutations and survival rates after first-line Egfr-tki treatment in patients with non-small cell lung cancer. Mol. Clin. Oncol. 11, 301\u2013308 (2019).","journal-title":"Mol. Clin. Oncol."},{"key":"38707_CR43","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s12094-015-1300-4","volume":"17","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients. Clin. Transl Oncol. 17, 727\u2013736 (2015).","journal-title":"Clin. Transl Oncol."},{"key":"38707_CR44","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl. J. Med. 361, 947\u2013957 (2009).","journal-title":"N Engl. J. Med."},{"key":"38707_CR45","doi-asserted-by":"publisher","first-page":"114542","DOI":"10.1016\/j.ejmech.2022.114542","volume":"239","author":"K Engle","year":"2022","unstructured":"Engle, K. & Kumar, G. Cancer multidrug-resistance reversal by ABCB1 inhibition: a recent update. Eur. J. Med. Chem. 239, 114542 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"38707_CR46","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ejmech.2017.07.062","volume":"142","author":"GL Beretta","year":"2017","unstructured":"Beretta, G. L., Cassinelli, G., Pennati, M., Zuco, V. & Gatti, L. Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. Eur. J. Med. Chem. 142, 271\u2013289 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"38707_CR47","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/genes15050591","volume":"15","author":"MV Morau","year":"2024","unstructured":"Morau, M. V., Seguin, C. S., Visacri, M. B., de Pincinato, E. & Moriel, P. C Genetic variants in the ABCB1 and ABCG2 gene drug transporters involved in gefitinib-associated adverse reaction: a systematic review and meta-analysis. Genes (Basel). 15, 591 (2024).","journal-title":"Genes (Basel)"},{"key":"38707_CR48","doi-asserted-by":"publisher","first-page":"806","DOI":"10.21037\/atm.2019.12.60","volume":"7","author":"Y Ma","year":"2019","unstructured":"Ma, Y. et al. The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. Ann. Transl Med. 7, 806\u2013806 (2019).","journal-title":"Ann. Transl Med."},{"key":"38707_CR49","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cllc.2014.12.004","volume":"16","author":"H Kobayashi","year":"2015","unstructured":"Kobayashi, H. et al. Relationship among gefitinib exposure, polymorphisms of its metabolizing enzymes and transporters, and side effects in Japanese patients with non-small-cell lung cancer. Clin. Lung Cancer. 16, 274\u2013281 (2015).","journal-title":"Clin. Lung Cancer"},{"key":"38707_CR50","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/bcpt.12997","volume":"123","author":"N Bj\u00f6rn","year":"2018","unstructured":"Bj\u00f6rn, N., Falk, J., Vergote, I., Gr\u00e9en, H. & I. & ABCB1 variation affects myelosuppression, progression-free survival and overall survival in paclitaxel\/carboplatin\u2010treated ovarian cancer patients. Basic. Clin. Pharmacol. Toxicol. 123, 277\u2013287 (2018).","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"38707_CR51","doi-asserted-by":"publisher","first-page":"100832","DOI":"10.1016\/j.drup.2022.100832","volume":"62","author":"N Heersche","year":"2022","unstructured":"Heersche, N. et al. Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer. Drug Resist. Updat. 62, 100832 (2022).","journal-title":"Drug Resist. Updat"},{"key":"38707_CR52","unstructured":"If no individual. author listed, you can use the organisation: C. Label Annotation: PA166182950-ClinPGx. ClinPGx https:\/\/www.clinpgx.org\/labelAnnotation\/PA166182950?utm_source=chatgpt.com"},{"key":"38707_CR53","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/17512433.2019.1597706","volume":"12","author":"R Cacabelos","year":"2019","unstructured":"Cacabelos, R., Cacabelos, N. & Carril, J. C. The role of pharmacogenomics in adverse drug reactions. Expert Rev. Clin. Pharmacol. 12, 407\u2013442 (2019).","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"38707_CR54","doi-asserted-by":"publisher","unstructured":"Hunt, R., Sauna, Z. E., Ambudkar, S. V., Gottesman, M. M. & Kimchi-Sarfaty, C. Silent (Synonymous) SNPs: should we care about them? in 23\u201339 (2009). https:\/\/doi.org\/10.1007\/978-1-60327-411-1_2","DOI":"10.1007\/978-1-60327-411-1_2"},{"key":"38707_CR55","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/0008-5472.CAN-13-2064","volume":"74","author":"KL Fung","year":"2014","unstructured":"Fung, K. L. et al. MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Cancer Res. 74, 598\u2013608 (2014).","journal-title":"Cancer Res."},{"key":"38707_CR56","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1038\/s41598-020-63265-4","volume":"10","author":"I. Zawadzka","year":"2020","unstructured":"Zawadzka, I. et al. The impact of ABCB1 gene polymorphism and its expression on non-small-cell lung cancer development, progression and therapy-preliminary report. Sci. Rep. 10, 6188 (2020).","journal-title":"Sci. Rep."},{"key":"38707_CR57","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","volume":"21","author":"LM Hodges","year":"2011","unstructured":"Hodges, L. M. et al. Very important pharmacogene summary. Pharmacogenet. Genomics 21, 152\u2013161 (2011).","journal-title":"Pharmacogenet. Genomics"},{"key":"38707_CR58","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/10915810600746023","volume":"25","author":"S Choudhuri","year":"2006","unstructured":"Choudhuri, S. & Klaassen, C. D.Structure function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 25, 231\u2013259 (2006).","journal-title":"Int. J. Toxicol."},{"key":"38707_CR59","doi-asserted-by":"publisher","first-page":"17895","DOI":"10.1038\/s41598-023-44792-2","volume":"13","author":"N Lalatovi\u0107","year":"2023","unstructured":"Lalatovi\u0107, N., \u017ddralevi\u0107, M., Antunovi\u0107, T. & Pantovi\u0107, S. Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin-induced muscle side effects: a cross-sectional study. Sci. Rep. 13, 17895 (2023).","journal-title":"Sci. Rep."},{"key":"38707_CR60","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer, S. et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97, 3473\u20133478 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"38707_CR61","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","volume":"2","author":"CC Schag","year":"1984","unstructured":"Schag, C. C., Heinrich, R. L. & Ganz, P. A. Karnofsky performance status revisited: reliability, validity, and guidelines. J. Clin. Oncol. 2, 187\u2013193 (1984).","journal-title":"J. Clin. Oncol."},{"key":"38707_CR62","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1136\/thx.37.5.343","volume":"37","author":"SK Jindal","year":"1982","unstructured":"Jindal, S. K., Malik, S. K., Dhand, R., Gujral, J. S. & Datta, B. N. Bronchogenic carcinoma in Northern India. Thorax 37, 343\u2013347 (1982).","journal-title":"Thorax"},{"key":"38707_CR63","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1159\/000152001","volume":"8","author":"DC Whitcomb","year":"2008","unstructured":"Whitcomb, D. C. et al. Multicenter approach to recurrent acute and chronic pancreatitis in the united states: the North American pancreatitis study 2 (NAPS2). Pancreatology 8, 520\u2013531 (2008).","journal-title":"Pancreatology"},{"key":"38707_CR64","doi-asserted-by":"publisher","DOI":"10.1053\/j.sult.2024.07.005","author":"LT Erasmus","year":"2024","unstructured":"Erasmus, L. T. et al. Imaging of lung cancer staging: TNM 9 updates. Semin. Ultrasound CT MRI. https:\/\/doi.org\/10.1053\/j.sult.2024.07.005 (2024).","journal-title":"Semin. Ultrasound CT MRI"},{"key":"38707_CR65","unstructured":"Instituto Brasileiro de Geografia e Estat\u00edstica (IBGE). Censo 2022. IBGE (2022). http:\/\/www.ibge.gov.br\/censo"},{"key":"38707_CR66","unstructured":"U.S Department of Health and Human Services. National Institute of Health NCI. U.S Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. (2018)."},{"key":"38707_CR67","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1186\/1471-2164-11-724","volume":"11","author":"RC Johnson","year":"2010","unstructured":"Johnson, R. C. et al. Accounting for multiple comparisons in a genome-wide association study (GWAS). BMC Genom. 11, 724 (2010).","journal-title":"BMC Genom."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38707-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38707-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38707-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:02:29Z","timestamp":1772845349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-38707-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["38707"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-38707-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by Ethics Committee of\n                      Faculdade de Ci\u00eancias M\u00e9dicas da Universidade Estadual de Campinas\n                      - Unicamp (protocol code 17328619.90000.5404, August 30, 2019). Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"8342"}}